NSEPress Release1d ago · 13 Oct 2026, 08:33 pm

Press Release

Zydus Lifesciences Limited · ZYDUSLIFE

✦ AI SummaryRegulatory

Zydus Lifesciences Limited has informed the Exchange that the USFDA inspection of its manufacturing plant at Moraiya, Ahmedabad, has concluded with 5 observations. The company will work with the USFDA to address these observations promptly.

Analysis Scores

Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk6/10
Balance Sheet Risk1/10
Liquidity Impact8/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated October 13, 2026, titled "USFDA inspection concludes at Zydus' manufacturing plant at Moraiya, Ahmedabad".

Attachments (1)

📄

Cadilahc_13102026203320_PressRelease13102026.pdf

pdf

Download →
View document text
October 13, 2026 BSE Limited Code: 532321 1st Floor, P J Towers, Dalal Street, Mumbai-400001 National Stock Exchange of India Limited Code: Zyduslife Exchange Plaza, 5th Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East), Mumbai-400051 Re.: Press Release Dear Sir / Madam, Please find enclosed a copy of press release dated October 13, 2026, titled “USFDA inspection concludes at Zydus' manufacturing plant at Moraiya, Ahmedabad”. The contents of the press release give full details. Please bring the aforesaid news to the notice of the members of the exchange and the investors’ at large. Thanking you, Yours faithfully, For, Zydus Lifesciences Limited Dhaval N. Soni Company Secretary and Compliance Officer Membership No. FCS7063 Encl.: As above USFDA inspection concludes at Zydus' manufacturing plant at Moraiya, Ahmedabad Ahmedabad, India, 13 October, 2026 We wish to inform that the USFDA conducted Inspection of the company’s manufacturing plant located at Moraiya, Ahmedabad. The inspection was conducted from 5th to 13th October 2026. The inspection closed with 5 observations. The Company will closely work with the USFDA to address the observations expeditiously. This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.